BB
DNDN

BB Biotech’s DENDREON CORPORATION DNDN Stock Holding History

BB Biotech’s Portfolio DNDN Stock Details DNDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-1,014,800
Closed -$4.18M – 27
2013
Q2 		$4.18M Buy
+1,014,800
New +$4.32M 0.3% 21

Other funds holding DNDN

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BB Biotech's DNDN Position: Q3 2013 in Review

BB Biotech sold out of DENDREON CORPORATION (DNDN) in Q3 2013, closing a stake of 1,014,800 shares — an estimated $4.18M sold.

BB Biotech first reported a position in DNDN in Q2 2013 and held it in 1 quarter. The position peaked at $4.18M in Q2 2013. 134 funds tracked by Wall St. Rank hold DNDN as of Q3 2013.

  • BB Biotech reported no remaining DENDREON CORPORATION position as of Q3 2013 after selling out during the quarter.
  • BB Biotech sold 1,014,800 DENDREON CORPORATION shares in Q3 2013, an estimated $4.18M.
  • BB Biotech first reported a position in DENDREON CORPORATION in Q2 2013 and held it in 1 quarter.
  • BB Biotech's DENDREON CORPORATION position peaked at $4.18M in Q2 2013.
  • 134 funds tracked by Wall St. Rank held DENDREON CORPORATION as of Q3 2013.

Based on BB Biotech's 13F filing for Q3 2013, filed 12 Nov 2013.